The US generics market is anticipated to grow at a CAGR of around 10% during 2010-2013, says our recent research report “Booming US Generic Drug Market. Currently, the market is witnessing significant developments in the form of new product categories that are attracting huge investments from both public and private players. The US government has welcomed their arrivals and extended support in the form of approvals and incentives. In terms of future scenario, major pharmaceutical players are likely to spend heavily on research and development as present market is in dynamic in nature and requires innovative products. Besides, these players will be consistently reviewing patent regime as through proactive approach, they will be able to launch their drugs first.

The generics market in the US has good growth potential in various therapy segments, which have attracted investments and market revenue in recent times. In this regard, our report provides rational analysis of various factors, which will drive the generics market in the US during the forecast period.

Overall, the report covers all the important aspects of the US generics market and provides an in-depth analysis on emerging trends, such as injectable generics, anti-counterfeit coalition, and bio-generics among others. It also provides valuable information to pharmaceutical & generics companies and investors looking to enter this market. Facts and figures regarding market size, growth, share, regulatory environment, and trends in technology development have been thoroughly analyzed in the report to provide clients a comprehensive overview of the market.